Changing the default for tobacco-cessation treatment in an inpatient setting: study protocol of a randomized controlled trial

被引:19
|
作者
Faseru, Babalola [1 ,2 ]
Ellerbeck, Edward F. [1 ,2 ]
Catley, Delwyn [3 ]
Gajewski, Byron J. [1 ,2 ]
Scheuermann, Taneisha S. [1 ,2 ]
Shireman, Theresa I. [4 ]
Mussulman, Laura M. [1 ,2 ]
Nazir, Niaman [1 ,2 ]
Bush, Terry [5 ]
Richter, Kimber P. [1 ,2 ]
机构
[1] Univ Kansas, Dept Prevent Med & Publ Hlth, Med Ctr, 3901 Rainbow Blvd, Kansas City, KS 66160 USA
[2] Univ Kansas, Canc Ctr, 3901 Rainbow Blvd, Kansas City, KS 66160 USA
[3] Childrens Mercy Hosp & Clin, Ctr Childrens Hlth Lifestyles & Nutr, Kansas City, MO USA
[4] Brown Univ, Providence, RI 02912 USA
[5] Optum, Seattle, WA USA
关键词
Tobacco use disorder; Smoking cessation; Hospital; Randomized clinical trial; Motivation; Treatment guidelines; SMOKING-CESSATION; SMOKERS; PREDICTORS; QUIT; ABSTINENCE; STRATEGIES; DEPENDENCE; MEDIATION; RELAPSE; DESIGN;
D O I
10.1186/s13063-017-2119-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Most health care providers do not treat tobacco dependence routinely. This may in part be due to the treatment "default." Current treatment guidelines recommend that providers (1) ask patients if they are willing to quit and (2) provide cessation-focused medications and counseling only to smokers who state that they are willing to quit. The default is that patients have to "opt in" to receive cessation assistance: providers ask smokers if they are willing to quit, and only offer medications and cessation support to those who say "yes." This drastically limits the reach of cessation services because, at any given encounter, only one in three smokers say that they are ready to quit. The objective of this study is to determine the impact of providing all smokers with tobacco-cessation treatment unless they refuse it (OPT OUT) versus current practice-screening for readiness and only offering treatment to smokers who say they are ready to quit (OPT IN). Methods: This individually randomized clinical trial is conducted in a tertiary-care hospital. We will conduct the trial among up to 1000 randomly selected hospitalized smokers to determine the population impact of changing the treatment default, identify mediators of outcome, and determine the cost-effectiveness of this new, highly proactive approach. This is a population-based study that targets an endpoint of vital interest; applies minimal eligibility criteria to broaden generalizability; and utilizes hospital staff for interventions to ensure long-term sustainability. The study employs delayed consent and an innovative Bayesian adaptive design to evaluate a major shift in our approach to care. If effective, this change would expand the reach of tobacco-cessation treatment from 30% to 100% of smokers. Discussion: Regardless of outcome, the trial will provide a model of how to alter and evaluate the impact of health care defaults. If OPT OUT proves to be more effective, it will expand the population eligible for cessation treatment by over 300%. It will also simplify the tobacco-cessation treatment algorithm, and relieve busy health care providers of the burden of evaluating readiness to quit.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Nicotine patch preloading for smoking cessation (the preloading trial): study protocol for a randomized controlled trial
    Nicola Lindson-Hawley
    Tim Coleman
    Graeme Docherty
    Peter Hajek
    Sarah Lewis
    Deborah Lycett
    Andy McEwen
    Hayden McRobbie
    Marcus R Munafò
    Steve Parrott
    Paul Aveyard
    Trials, 15
  • [32] Nicotine patch preloading for smoking cessation (the preloading trial): study protocol for a randomized controlled trial
    Lindson-Hawley, Nicola
    Coleman, Tim
    Docherty, Graeme
    Hajek, Peter
    Lewis, Sarah
    Lycett, Deborah
    McEwen, Andy
    McRobbie, Hayden
    Munafo, Marcus R.
    Parrott, Steve
    Aveyard, Paul
    TRIALS, 2014, 15
  • [33] Testing the feasibility of a guided imagery tobacco cessation intervention delivered by a telephone quitline: Study protocol for a randomized controlled feasibility trial
    Gordon, Judith S.
    Giacobbi, Peter, Jr.
    Armin, Julie S.
    Nair, Uma S.
    Bell, Melanie L.
    Povis, Gayle
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 16
  • [34] N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial
    Arancini, Lauren
    Bortolasci, Chiara C.
    Dodd, Seetal
    Dean, Olivia M.
    Berk, Michael
    TRIALS, 2019, 20 (01)
  • [35] Offering Population-Based Tobacco Treatment in a Healthcare Setting A Randomized Controlled Trial
    Rigotti, Nancy A.
    Bitton, Asaf
    Kelley, Jennifer K.
    Hoeppner, Bettina B.
    Levy, Douglas E.
    Mort, Elizabeth
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2011, 41 (05) : 498 - 503
  • [36] N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial
    Lauren Arancini
    Chiara C. Bortolasci
    Seetal Dodd
    Olivia M. Dean
    Michael Berk
    Trials, 20
  • [37] Effectiveness of the national German quitline for smoking cessation: study protocol of a randomized controlled trial
    Delle, Simone
    Kraus, Ludwig
    Maspero, Simona
    Pogarell, Oliver
    Hoch, Eva
    Lochbuhler, Kirsten
    BMC PUBLIC HEALTH, 2022, 22 (01)
  • [38] Approach bias retraining to augment smoking cessation: Study protocol for a randomized controlled trial
    Smits, Jasper A. J.
    Baird, Scarlett O.
    Rinck, Mike
    Rosenfield, David
    Beevers, Christopher G.
    Brown, Richard A.
    Conroy, Haley E.
    Alavi, Noura
    Dutcher, Christina D.
    Freeman, Slaton Z.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 14
  • [39] Effectiveness of the national German quitline for smoking cessation: study protocol of a randomized controlled trial
    Simone Delle
    Ludwig Kraus
    Simona Maspero
    Oliver Pogarell
    Eva Hoch
    Kirsten Lochbühler
    BMC Public Health, 22
  • [40] Electroacupuncture treatment for sarcopenia: study protocol for a randomized controlled trial
    Hao Li
    Li Zhou
    Xin Zhang
    Qian Wen
    Li Tian
    Han Yang
    Xirong Chen
    Jinghan Yuan
    Ning Li
    Bingmei Zhu
    Lin Zhang
    Lingyun Lu
    BMC Complementary Medicine and Therapies, 24 (1)